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The treatment of advanced bladder cancer frequently involves the
use of intensive chemotherapy. Recent randomized trials suggest
that the use of regimens such as M-VAC or CMV improves
disease-free and overall survival (Logothetis et al, 1990; Loehrer
et al, 1992; Fosså et al, 1996). A group of good prognosis patients
with good performance status and disease confined to the pelvis
may have a 5-year survival rate of up to 28% (Fosså et al, 1996).
However, the median survival of patients with metastatic disease
who do not have these good prognostic features is only 10 months
(Fosså et al, 1996). Patients are frequently elderly, frail and may
have impaired renal function, and toxicity is significant, with 4%
treatment-related mortality (Sternberg et al, 1988; Loehrer et al,
1992; Fosså et al, 1996). Only patients who have a good response
to chemotherapy seem to gain significant survival benefit (Fosså et
al, 1996), so early assessment of response is desirable to avoid
unnecessary toxicity in patients who are not responding to treat-
ment and may have a limited life expectancy. In several tumour
types (for example, testicular germ cell tumours and prostate
cancer) tumour markers, when raised, can play a useful role in
monitoring response to treatment and have resulted in important
improvements in management.
In bladder cancer several tumour markers have been reported as
being raised including b human chorionic gonadotrophin (bhCG),
carcinoembryomic antigen (CEA), CA 19.9, CA 125 and tissue
polypeptide antigen (TPA). bhCG is the most widely reported and
has been found both in the serum and urine (Dexeus et al, 1986;
Iles et al, 1989, 1996; Williams et al, 1990; McLoughlin et al,
1991; Marcillac et al 1992, 1993) and on immunohistochemical
staining (Wurzel et al, 1987; Moutzouris et al, 1993) in many
patients with bladder cancer. Iles et al (1989) report that serum
levels of bhCG were raised in 76% of patients with widespread
metastases but only 3% with disease confined to the pelvis (Iles
et al, 1989). Other estimates of the frequency with which bhCG
is elevated vary from 14% (McLoughlin et al, 1991) to 47%
(Marcillac et al, 1992). In preliminary work in patients with
locally advanced/metastatic disease, who have significantly raised
tumour markers, marker levels have been shown to correlate with
the clinical course of the disease (Marcillac et al, 1992) and
response to chemotherapy (Dexeus et al, 1986; Marcillac et al,
1993).
Other markers are less commonly described, although Dexeus
et al (1986) found CEA to be raised in 23% of patients with
advanced bladder cancer referred for chemotherapy the level
correlating with clinical response (Dexeus et al, 1986). CA 19.9
has been found to be raised, in up to 40% (8/20) patients with
bladder cancer (Abel et al, 1987; Pectasides et al, 1996). CA125
was reported as raised in one patient with adenocarcinoma of the
urachus, which fell with response to chemotherapy (Guarnaccia
et al, 1991). Recently TPA has also been reported to be a sensitive
marker of bladder cancer (particularly advanced or metastatic
disease) (Maulard Durdux et al, 1997) and may be useful in moni-
toring response to treatment (Schmidt et al, 1992; Pectasides et al,
1996).
The aim of this study was to assess how often certain tumour
markers were raised in patients receiving chemotherapy for locally
advanced or metastatic bladder cancer and to determine whether
they could have a role in monitoring the response to treatment. It
was previously decided to concentrate on the markers shown to be
raised for which tests were routinely available at our Institution
(bhCG, CEA, CA19.9 and CA125).
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Summary In patients with advanced bladder cancer receiving chemotherapy, early assessment of response can avoid unnecessary toxicity.
The aim of this study was to assess the role of tumour markers in monitoring response. Serum levels of one or more of markers b human
chorionic gonadotrophin (bhCG), carcinoembryomic antigen (CEA), CA125 and CA19.9 were measured in 74 patients with advanced bladder
cancer receiving chemotherapy from 1992 to 1997. Forty-three of 74 (58%) of patients had at least one raised marker (1.5 times upper limit
of normal range). This was more common in patients with extra-pelvic disease than in those with disease confined to the pelvis (P = 0.002).
Thirty-eight of 78 (49%) assessable patients had a radiological response. Neither clinical response (P = 0.81) nor survival (P = 0.16) differed
between marker-negative and marker-positive patients. Clinical response was strongly related to marker response in the 35 comparable
patients (P = 0.0001). No patient had a clinical response without response of at least one marker. Ninety per cent of patients who achieved a
marker response had done so by 8 weeks. Monitoring of tumour markers in patients with advanced bladder cancer can help predict the
response to chemotherapy. © 2000 Cancer Research Campaign
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PATIENTS AND METHODS
From July 1992 to July 1997 serum levels of tumour markers were
measured in 74 of 78 patients with locally advanced or metastatic
bladder cancer referred for consideration of chemotherapy.
The most common regimen used was M-VAC (Sternberg et al,
1988) (methotrexate 30 mg m–2 on days 1, 15, 22, vinblastine
3 mg m–2 on days 1, 15, 22, doxorubicin 30 mg m–2 on day 1,
cisplatin 70 mg m–2 on day 1). Twenty-three patients had modified
regimens. Fifteen patients were given carboplatin instead of
cisplatin, methotrexate was omitted in three patients (with pleural
effusions or ascites), one patient did not receive doxorubicin
because of impaired hepatic function and vinblastine was omitted
in two patients. Two patients were treated with carboplatin and
methotrexate only. The median number of cycles given was three
(range 1–6).
At the start of the study only bhCG and CEA were measured
routinely. From November 1994 CA19.9 was added, but CA125
was only routinely checked from May 1996. Marker analysis was
performed on a Roche Cobas Core analyser (Roche Diagnostics)
until December 1996 and thereafter on an Abbott Axsym analyser
(Abbott Diagnostic Laboratories). Normal ranges as per manufac-
turing reccomendations (bhCG < 4 IU L–1, CEA < 5 mg ml–1,
CA19.9 < 35 U ml–1 and CA125 < 35 U ml–1). Levels above the
normal range were noted but only those of 1.5 times the upper
limit of the normal range were classified as being raised. Also 1.5
times the upper limit was chosen in line with some systems of
prognostic grouping where a marker raised more than minimally
to 1.5 times is considered abnormal (International Germ Cell
Cancer Collaborative Group, 1997). It was aimed to repeat any
markers that were raised prior to chemotherapy on day 1 of each
cycle of chemotherapy. Those that were not raised prior to treat-
ment were not repeated as they were unlikely to be raised and it
was not considered to be cost-effective.
Sites of disease were recorded prior to chemotherapy. Patients
with pelvic nodal or locally advanced disease only were classified
as having pelvic disease and all others were considered to have
extra-pelvic disease. Clinical response was assessed according to
radiological findings by a consultant radiologist after 2, 4 and 6
cycles of chemotherapy. A complete response (CR) representing
no radiological evidence of disease and a partial response (PR) a
considerable reduction in disease volume equivalent to 50% or
more. Stable or progressive disease was classified as no response.
Marker response was defined as a 50% fall in marker levels and
complete response as return of markers to normal levels.
Individual marker responses were compared with clinical
response, but in cases where more than one marker was raised and
there had been a differing response between the markers, the
response in the marker showing the greatest and that showing the
poorest response were also recorded and compared with clinical
response. These were recorded as ‘best’ and ‘worst’ marker
response respectively.
Statistical analysis
Categorical data were examined using the c2 test with Fisher’s
Exact test (one-tail, P-values) where appropriate. Survival analysis
was performed using the methods of Kaplan and Meier and differ-
ences in survival curves examined using the log-rank test. Figure 1
was generated using the methods of Kaplan and Meier but any
marker response (partial or complete) was considered as the event.
RESULTS
There was a total of 78 patients who received chemotherapy for
bladder cancer during this period. Patient characteristics are given
in Table 1.
Frequency of raised markers in patients with bladder
cancer
One or more pre-treatment tumour marker was checked in 74 of
the 78 patients. Overall, 43 of the 74 (58%) patients had at least
one marker more than 1.5 times the upper limit of the normal
range. Fifty-two of 74 (70%) had elevation of at least one marker
above the normal range.
At least one tumour marker was more frequently raised in
patients known to have extra-pelvic disease (34/47, 72%) than
in those who had disease confined to the pelvis (9/27, 33%)
(P = 0.001). This was not clearly demonstrated when analysing
individual markers as the numbers were too small.
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Table 1 Patient characteristics
Patient characteristic Number of patients
Sex
Male 64
Female 14
Age
Median 62 years (36–75)
Sites of disease
Pelvic 29
Bladder alone 7
Pelvic lymph nodes+/–bladder 22
Extra-pelvic 49
Para-aortic nodes 18
Lung 16
Liver 7
Bone 11
Othera 25
Histology
Transitional cell 73
Adenocarcinoma 1
Squamous 0
Undifferentiated 4
a Including psoas muscle, mediastinal lymph nodes, pleural effusions.1954 AM Cook et al
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Twenty-one of 71 (30%) of patients had a significantly raised
bhCG, 16 of 67 (24%) a raised CEA, 19 of 44 (43%) a raised
CA19.9 and three of 21 (14%) a raised CA125. Fourteen of the 43
patients with raised markers had more than one marker raised
(12 had two raised markers and two had three) with 29 of 43
having one only.
The median values (range), of markers before treatment were
bhCG (median 81, range 7–3303), CEA (median 40, range
10–1280), CA19.9 (median 236, range 59–10920) and CA125
(median 142.5, range 128–157). Mean levels (range), after treat-
ment were bhCG (mean 2, range 2–58), CEA (mean 11, range
1–272), CA19.9 (mean 121, range 6–8730) and CA125 (mean 23,
range 16–30).
Response
Of the 78 patients treated, seven died early in their treatment, five
after only one cycle of chemotherapy and two just after the second
cycle (despite early suggestions of response). These have all been
classified as non-responders.
The overall clinical response rate was 38 of 78 patients (49%),
of which ten of 78 (13%) had a complete response and 28 of
78 (36%) had a partial response. For patients with extra-pelvic
disease overall response rate was 22 of 49 (44.9%, confidence
interval (CI) 30.7–59.8) and for pelvic disease 16 of 29 (55.2%, CI
35.7–73.6)). The difference was not significant (P = 0.38). There
was no significant difference in response rate in all patients with
one or more positive markers compared with that in patients with
negative markers (P = 0.81) (see Table 2), suggesting that the pres-
ence of a raised pretreatment marker to > 1.5 times the normal
range is not a useful prognostic factor for response in patients with
metastatic disease.
The proportion of patients with a marker response varied
according to the individual marker. In patients with a raised bhCG,
18 of 19 achieved a response, while only eight of 14 patients with
a raised CEA and eight of 14 patients with a raised CA 19.9
responded.
Table 3 shows the clinical response compared to the marker
response (in evaluable patients) for each tumour marker in turn.
The numbers were small; however, there was a suggestion that
marker response was related to clinical response, especially with
Table 2 Clinical response in patients with negative markers compared to those with one or more positive markers
Clinical response
No. raised markers Complete response Partial response No response Total
0 3 12 16 31
1 or more 7 15 21 43
Not known 0 1 3 4
Total 10 28 40 78
Chi-squared test of responders (with complete or partial response) compared with non-responders for patients with positive or
negative markers P = 0.81.
Table 3 Clinical response compared to marker response in evaluable patients
Clinical response
Complete response Partial response No response Total
bhCG responsea
Complete 2 9 4 15
Partial 1 1 1 3
No response 0 0 1 1
Total 3 10 6 19
CEA responseb
Complete 2 1 0 3
Partial 2 1 2 5
No response 0 1 5 6
Total 4 3 7 14
Ca19.9 responsec
Complete 1 1 1 3
Partial 0 4 1 5
No response 0 0 5 5
Total 1 5 7 13
Ca125 response
Complete 0 1 1 2
Partial 0 0 0 0
No response 0 0 0 0
Total 0 1 1 2
a Fisher’s exact test of responders (complete or partial) vs non-responders P = 0.32 (one-tail). b Fisher’s exact test (one tail) of responders vs non-responders
P = 0.052. c Fisher’s exact test (one-tail) of responders vs non-responders P = 0.17.CEA (P = 0.051) and CA19.9 (P = 0.17). It appears that bhCG
may overestimate response. Tables 4A and 4B show that the clin-
ical response is strongly related to both the ‘worst’ (that showing
the least response where more than one marker was raised)
(P < 0.0001), and ‘best’ (that showing the greatest) marker
response (P = 0.0017). Figure 1 shows the probability of achieving
a partial marker response. There was a 46% chance of responding
by 4 weeks, with a 72% chance of responding by 8 weeks. Only
three of 29 patients who did have a partial marker response had not
responded by 8 weeks, thus 90% of patients who eventually did
have a partial marker response had done so by 8 weeks. The three
patients achieving a marker response after this time did so at 68, 77
and 114 days, but this apparent delay may be misleading. In all
three the markers had fallen early in treatment but were not
checked at 8 weeks and by the time they were subsequently
checked a response had been achieved. Of the 29 patients who
eventually achieved a marker response, markers had been checked
after 4 weeks in 23. In all of these the responding marker had
fallen by at least 35% by 4 weeks. The median time to achieve at
least a partial marker response was 29 days (range 14–114).
If the ‘worst’ marker response is considered it can be seen that
in 18 of 36 patients the marker response was the same as the
clinical response and in 14 of 36 patients the marker response was
better than the clinical response. In five cases serum markers
predicted response but clinical response was not demonstrated.
There was, however, only one patient who had no marker response
but did have a clinical response. In this patient the CEA was
initially only slightly raised at 10 and it fell to 8 during treatment.
This patient also had a more markedly raised bhCG at 188, which
fell substantially to 5 during treatment. Overall the sensitivity was
95% and specificity 69%.
When considering the ‘best’ marker responses, it is notable that
nine patients had a marker response with no definite clinical
response. In one of these patients there was a differential response
with lung metastases resolving with treatment (coinciding with
a fall in bhCG from 7 to 2) but a pelvic mass subsequently
increasing in size. In five of these nine patients another marker was
also raised, and in four of these the other marker showed no
response. Thus, the sensitivity was 100%, but specificity was
reduced to 44%.
Survival
As expected, overall survival was poor but the patients with
disease confined to the pelvis (median survival 24 months)
survived significantly longer than those with extra-pelvic disease
(median survival 9 months) (P = 0.006) (Figure 2).
There was no difference in survival between marker positive
and marker negative patients (P = 0.155) (Figure 3). Small
numbers made it difficult to compare survival in patients who
achieved a marker response with those who did not achieve a
marker response.
DISCUSSION
A high proportion of patients with metastatic bladder cancer have
one or more raised tumour markers. This is especially true for
patients with extra-pelvic disease in whom, in this series, 70% had
at least one marker significantly raised. By nature of the evolution
of this project not all patients had all markers checked so this may
represent the lower end of the expected rate. The increased
frequency of marker elevation in extra-pelvic disease suggests that
the presence of raised tumour markers is related to tumour bulk.
In this study, however, there was no definite evidence of raised
pretreatment tumour markers being a poor prognostic factor, in
Tumour markers in bladder cancer 1955
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Table 4 Clinical response compared to ‘worst’ marker response in evaluable patients
Clinical response
Complete response Partial response No response Total
‘Worst’ marker response
Complete 3 9 4 16
Partial 3 4 1 8
No response 0 1 11 12
Total 6 14 16 36
‘Best’ marker response
Complete 4 12 6 22
Partial 2 2 3 7
No response 0 0 7 7
Total 6 14 16 36
a Fisher’s exact test (one tail) of responders vs non-responders P < 0.0001; Sensitivity 95%, Specificity 69%.b Fisher’s exact test (one tail) of responders vs
non-responders P = 0.0017; Sensitivity 100%, Specificity 44%.
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patients with metastatic disease. However, the study only has
limited power and this result may be confounded by some earlier
patients only having one, or more commonly two, markers
measured and thus not representing truly marker-negative patients.
Previous studies (Dexeus et al, 1986; McLoughlin et al, 1991)
which have found bhCG to be a poor prognostic factor have been
in patients with localized disease. Iles et al (1996) investigated
urinary hCG levels. In this study urinary bhCG levels in patients
with T2–T4 disease were significantly associated with develop-
ment of metastases and survival. Moutzouridis et al (1993) looked
at immunohistochemistry of biopsies from patient with apparently
localized bladder cancer and noted a significant difference in
response to radiotherapy with bhCG-positive tumours responding
poorly and these patients tended to have a worse survival.
There is a clear relationship between marker response and clin-
ical response. It might be expected that a raised tumour marker
would respond more rapidly to treatment than radiological appear-
ances. The evidence presented here suggests that if a marker
response is to occur it occurs quickly, with 90% of responders
having had a 50% fall by 2 months and some degree of fall by 4
weeks. As markers were largely only taken when patients attended
for treatment this, if anything, represents a ‘worst’ case situation
and that marker response could be detected as early as 4–6 weeks
after treatment is commenced. It is also clear from our data that in
the presence of stable or rising marker levels radiological response
is unlikely and would suggest that alternative treatment strategies
should be pursued.
The converse is not always true with a proportion of patients
achieving a marker response without clinical evidence of a partial
response. This was particularly noticeable with bhCG, where five
of 19 patients had a marker response but no clinical response.
Similar effects have been seen in prostate-specific antigen levels in
prostate cancer following chemotherapy and could be due to a
number of mechanisms including clonal selection of non marker
secreting cells or modification of marker secretions by tumour
cells in response to chemotherapy.
The specificity of the marker response was increased when
more than one marker was followed. The ‘worst’ marker response,
in particular, was very closely related to clinical response. A policy
of testing initially for all four tumour markers mentioned (and then
following only the raised marker) increases the chances of finding
a raised marker and, where more than one is raised, the accuracy
with which response can be predicted. We are now using this
policy as part of our routine management for patients receiv-
ing palliative chemotherapy for bladder cancer. Response to
chemotherapy is often difficult to assess and if at least one marker
is raised pre-treatment but does not fall with treatment and unless
there was often clear indication of response we would stop
chemotherapy after two cycles, so saving unnecessary toxicity for
the patient and cost for the hospital.
Recently TPA has also been used as a marker for monitoring
therapeutic efficacy in bladder cancer (Pectasides et al, 1996),
including after MVEC chemotherapy (Schmidt et al, 1992). It was
found to be a sensitive marker (although sensitivity depends on the
definition of the upper limit of the normal range) (Maulard Durdux
et al, 1997) and complete marker response correlated well with
complete clinical response. If this assay is readily available it may
be useful combined with the markers used in this study or possibly
further markers to increase the sensitivity of this approach.
In summary, these findings suggest that monitoring a panel of
currently available tumour markers in bladder cancer can help
predict the clinical response of patients to chemotherapy. Further
investigation of these markers, with other newer ones, in advanced
bladder cancer is indicated to obtain more information on the
relative worth of individual markers and more details on the
characteristics of marker response.
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